Mania. Manic episode
Conditions
Interventions
Intervention 1: Both groups of patients will receive similar sodium valproate. placebo with similar appearance, dosage, and from same pharmaceutical company in control group. Intervention 2: Both grou
Placebo
Treatment - Drugs
Both groups of patients will receive similar sodium valproate. placebo with similar appearance, dosage, and from same pharmaceutical company in control group.
Both groups of patients will receive similar sodium valproate. Allopurinol 600 mg daily (300 mg twice daily) in intervention group.
Sponsors
Research Center for Behavioral Disorders And Substance Abuse
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients who are admitted to psychiatric wards of Farshchian Psychiatry Hospital, Hamedan, Iran, for acute phase of mania according to DSM IV-TR. Exclusion criteria: 1) General health priority; 2) Having other psychiatric diagnostics such as schizophrenia, anxiety disorders and etc; 3) Consumption of substance or dependence on alcohol during the past month; 4) Existence of prominent problem in their laboratory tests; 5) History of serious cardiac, respiratory, nervous, endocrine, kidney disease, and uncontrolled diabetes; 6) Pregnancy and breastfeeding; 7) Consumption of drugs such as Azathioprine, Mercaptopurine, Apalcillin, Amoxicillin, Ampicillin, Warfarin and Theophylline; 8) Sensitivity to Allopurinol; 9) The need for ECT during the treatment; 10) Having YMRS < 17.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mania. Timepoint: 1, 7, 14, 21, 28 days or at the end of treatment. Method of measurement: YMRS and CGI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Uric acid. Timepoint: 1, 28 days or at the end of treatment. Method of measurement: Serum level. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Mohamad Haghighi
Hamadan University of Medical Sciences
Outcome results
None listed